Shots:

• The approval is based on P-III ESAX-HTN study assessing esaxerenone vs eplerenone for 12wks. in patients with essential hypertension- 1EP as SBP / DBP
• In 2006- Exelixis and Daiichi Sankyo collaborated to develop and commercialize and Esaxerenone tablets. Exelixis will receive $20M milestone on sales and has received additional $20M as on regulatory milestones in Q1’18
• Minnebro tablets (1.25/2.5/5 mg) are antihypertensives drug used for blocking mineralocorticoid receptor activation and is evaluated in P-III for diabetic nephropathy by Daiichi

Ref: Exelixis | Image: Daiichi Sankyo